Pulmonary complications in lymphoma patients treated with high-dose therapy autologous bone marrow transplantation.
To define the incidence and spectrum of pulmonary complications following autologous bone marrow transplantation (BMT), we retrospectively reviewed the course of 77 consecutive patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) who failed conventional therapy and underwent autologous BMT. Forty-five percent of the 77 patients developed respiratory complications with a mortality from pulmonary causes of 26%. A total of 38 episodes of respiratory compromise occurred in 35 patients. Infections accounted for 15 episodes (39%) and included bacterial (16%), Aspergillus (8%) cytomegalovirus (8%), Herpes simplex (3%), and other (5%) pneumonias. The spectrum of infections was similar to that reported following allogeneic BMT, but cytomegalovirus pneumonia was not as frequent a problem in those with autologous transplant. Mortality from pulmonary infections was 33%. Noninfectious disorders accounted for 23 episodes (61%) and included recurrent HD (18%), radiation/drug toxicity (16%), and acute respiratory failure thought secondary to pulmonary alveolar hemorrhage (26%). This latter entity developed acutely within 2 wk following BMT and was associated with use of thoracic radiation for treatment of malignant disease in the chest just prior to BMT (p < 0.05). It was not associated with the age of the patient or presence of thrombocytopenia, coagulopathy, renal insufficiency or neutropenia (p NS). Mortality from noninfectious causes was 65%, but in those with pulmonary hemorrhage it was 100%. In conclusion, pulmonary complications are a major source of morbidity and mortality in patients with HD and NHL undergoing autologous BMT.(ABSTRACT TRUNCATED AT 250 WORDS)
Jules-Elysee
K
K
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.
Stover
D E
DE
Yahalom
J
J
White
D A
DA
Gulati
S C
SC
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000379:methods; D002173:Cancer Care Facilities; D015984:Causality; D002423:Cause of Death; D003131:Combined Modality Therapy; D005260:Female; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D015994:Incidence; D008171:Lung Diseases / Q000453:epidemiology* / Q000209:etiology / Q000401:mortality; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D009519:New York City / Q000453:epidemiology; D012189:Retrospective Studies; D013997:Time Factors; D014182:Transplantation, Autologous / Q000009:adverse effects* / Q000379:methods; D014916:Whole-Body Irradiation / Q000009:adverse effects